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Abstract: Curcumin has been well studied for its anti-oxidant, anti-inflammatory, and anti-cancer
action. Its potential as a therapy is limited due to its low bioavailability and rapid metabolism.
To overcome these challenges, investigators are developing curcumin analogs, nanoparticle
formulations, and combining curcumin with other compounds or dietary components. In the
present study, we used a 1-chromonyl-5-imidazolylpentadienone named KY-20-22 that contains both
the pharmacophore of curcumin and 1,4 benzopyrone (chromone) moiety typical for flavonoids,
and also included specific moieties to enhance the bioavailability. When we tested the in vitro
effect of KY-20-22 in triple-negative breast cancer (TNBC) cell lines, we found that it decreased
the cell survival and colony formation of MDA-MB-231 and MDA-MB-468 cells. An increase
in mitochondrial reactive oxygen species was also observed in TNBC cells exposed to KY-20-22.
Furthermore, KY-20-22 decreased epithelial–mesenchymal formation (EMT) as evidenced by the
modulation of the EMT markers E-cadherin and N-cadherin. Based on the fact that KY-20-22 regulates
interleukin-6, a cytokine involved in chemotherapy resistance, we combined it with paclitaxel and
found that it synergistically induced anti-proliferative action in TNBC cells. The results from this
study suggested that 1-chromonyl-5-imidazolylpentadienone KY-20-22 exhibited anti-cancer action in
MDA-MB-231 and MDA-MB-468 cells. Future studies are required to evaluate the anti-cancer ability
and bioavailability of KY-20-22 in the TNBC animal model.
Keywords: curcumin; triple-negative breast cancer; paclitaxel; IL-6
1. Introduction
Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) is one of the major
polyphenols present in turmeric. Traditionally, turmeric has been used in South Asian countries for
microbial infections and any kind of inflammation. Recent studies demonstrated the vast action of
curcumin as an anti-oxidant, anti-inflammatory, anti-cancer, and anti-microbial agent [1–5], and its
anti-proliferative and anti-metastatic action has been established in breast cancer [3–5]. Studies have
explored the potential use of curcumin in triple-negative breast cancer (TNBC), a subtype of breast
cancer that lacks available therapeutic targets, such as the estrogen receptor (ER) and HER2, as well
as the progesterone receptor. Chemotherapy is the current standard therapy for TNBC; however,
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most patients develop resistance towards the treatment, which results in tumor recurrence and cancer
metastasis [6]. One of the other characteristics of TNBC is the BRCA1 mutation in the hereditary
phenotype and the silencing of wild type BRCA1 in the sporadic phenotype [7]. Studies have suggested
that curcumin could re-express BRCA1 expression in TNBC [8]. Curcumin-exposed HCC-38 and
UACC-3199 cells expressed BRCA1 gene expression by reducing the DNA promoter methylation
level [9]. Curcumin increased wild type BRCA1 protein expression, phosphorylation, and cellular
localization, but not those of mutant BRCA1 [10]. Our recent studies have also suggested that curcumin
enhances wild type BRCA1 by modulating chromatin histone acetylation [8].
Various signaling pathways have been detected in curcumin’s anti-cancer activity [11,12]. A major
challenge facing curcumin therapy is its low bioavailability, which is due to poor absorption, rapid
metabolism, and rapid elimination [13]. To overcome these challenges, various strategies have been
identified to improve curcumin action in a physiological system, including the development of curcumin
analogs, various types of nanoparticle formulations, and the combination of other dietary components
with curcumin [13–15]. Curcumin exhibited higher anti-cancer action when it was combined with
piperine [16]. A study in breast cancer cells identified that curcumin and piperine reduced breast
stem cell self-renewal by targeting lipid metabolism, specifically reducing the stearoyl-CoA desaturase
enzyme [17]. A variety of studies have found that curcumin increases its anti-cancer action when
it is combined with quercetin, a major polyphenol present in fruits and vegetables [18]. It has been
recognized widely for its anti-oxidant and anti-inflammatory action, and reports are also available on its
anti-cancer action for various cancers [19,20]. Individually, the bioavailability of curcumin and quercetin
is significantly low [21,22]. Studies have shown, however, that quercetin enhances the bioavailability
of curcumin in cancer cells [23]. Zhang et al. reported that a combined treatment of curcumin and
quercetin increased the apoptosis of gastric cancer cells via the mitochondrial pathway [24]. Our recent
studies suggested that the combination of curcumin and quercetin synergistically activated BRCA1
expression and inhibited TNBC cell survival compared to individual treatments of curcumin and
quercetin [8]. Another study reported the synergistic anti-proliferative action of curcumin and quercetin
in various cancer cells [25]. Mutlu Altundag et al. reported that the combined administration of
curcumin and quercetin increases the apoptosis of chronic myeloid cells [26]. Ongoing investigations
are focusing on different delivery systems of these compounds using nanoparticles [27,28]. For instance,
a very recent study by Mansourizadeh et al. showed that apoferritin nanoparticles loaded with
quercetin and curcumin (Que-Cur-HoS-Apo NPs) exhibited a synergistic anti-tumor effect in MCF-7
breast cancer cells [29].
Our approach was to use the dienone KY-20-22 (3-((1E,4E-5-(1-ethyl-1H-imidazol-2-yl)-3-oxopenta-
1,4-dien-1-yl)-4H-chromen-4-one), which contains the pharmacophore of curcumin and
1,4-benzopyrone (chromone) moiety typical for flavonoids including quercetin. This compound
possesses a nitrogen-containing heteroaromatic ring, a molecular weight of 320, a Clog P of 1.89, and a
tPSA of 59, implying a high probability of its good oral bioavailability. Earlier studies demonstrated
that this compound exhibits anti-proliferative action in prostate cancer cells [30]. The five-membered
heterocyclic ring in the dienone has been established as the optimal bioisostere of the phenyl ring
in curcumin by making significant contributions to the improved potency in prostate cancer cells
and superior bioavailability in rats [31]. Our present study concentrated on the in vitro effect
of this 1-chromonyl-5-imidazolylpentadienone KY-20-22 in TNBC cell line models. The dienone
dose-dependently inhibited the cell survival and growth of TNBC cell lines MDA-MB-231 and
MDA-MB-468. Based on findings that a combination of different chemotherapy drugs or the addition of
any therapeutic molecule to chemotherapy drugs enhances the anti-cancer action of the chemotherapy,
the present study studied the influence of KY-20-22 on the anti-cancer action of paclitaxel. Our results
suggested a synergistic action of paclitaxel and KY-20-22 against TNBC cells.
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2. Results
2.1. Anti-Proliferative Action of 1-Chromonyl-5-Imidazolylpentadienone KY-20-22 in TNBC Cell Lines
Our previous study suggested that curcumin and quercetin act synergistically to inhibit
the cell growth of TNBC cells compared to individual treatment [8]. The present study
used 1-chromonyl-5-imidazolylpentadienone, KY-20-22, which contains the pharmacophore of
both curcumin and quercetin. The previous study suggested that this dienone induced an
anti-proliferative effect in prostate cancer cells [30]. Further study found that this dienone is more
potent and exhibit higher bioavailability compared to curcumin [31]. To determine the effect of
1-chromone-5-imidazolepentadienone KY-20-22 on TNBC cell survival, an MTT assay was carried out
using different doses (0–50 µM) of KY-20-22 for different time courses (24, 48, and 72 h) in MDA-MB-231
and MDA-MB-468 cells. The results suggested a dose-dependent inhibition of the cell survival of both
cell lines.
After 72 h of treatment, a 10µM concentration of KY-20-22 reduced the cell survival of MDA-MB-231
by approximately 60% (p < 0.001) and that of MDA-MB-468 by approximately 68% (p < 0.001)
(Figure 1A,B). The IC50 value of KY-20-22 was approximately 5 µM for both MDA-MB-231 and
MDA-MB-468 cells. Further to determine the effect of KY-20-22 on the growth of MDA-MB-231 and
MDA-MB-468 cells, a trypan blue assay was carried out with different concentrations (0–10 µM)
of KY-20-22 for different time intervals (24, 48, and 72 h). Vehicle-treated control (0 µM) showed
time-dependent growth of both MDA-MB-231 and MDA-MB-468 cells, whereas KY-20-22-treated
MDA-MB-231 and MDA-MB-468 cells exhibited a dose-dependent reduction of cell growth, and a
significant reduction was observed with a 0.5–1 µM concentration of KY-20-22 (p < 0.001, Figure 1C,D).
Furthermore, the effect of KY-20-22 was tested in T47D cells, an ER-positive breast cancer line, to test
whether the action of KY-20-22 is specific to TNBC cells. We found that KY-20-22 was more effective in
TNBC cells compared to T47D. The IC50 value of KY-20-22 for T47D was 50 µM. This is 10 times higher
than that required for MDA-MB-231 and MDA-MB-468 cells (Figure 1E,F).
The inhibition of cell growth by KY-20-22 was further confirmed by a colony formation assay.
The results revealed a dose-dependent response, where even a 1 µM concentration of KY-20-22
decreased (p < 0.05) the colony formation, and treatment with a 10 µM concentration of KY-20-22
had a significant effect in reducing the colony formation of both MDA-MB-231 and MDA-MB-468
cells compared to vehicle-treated cells (p < 0.001) (Figure 2A–D). These studies indicate that KY-20-22
treatment significantly reduced TNBC cell line growth.
Furthermore, we carried out experiments to assess whether KY-20-22 treatment increases ROS
generation in MDA-MB-231 cells. Mitochondrial ROS generation was determined in real time using
fluorescent MitoSox Red superoxide indicator in MDA-MB-231 cells treated with KY-20-22. The results
suggested that KY-20-22 significantly increased mitochondrial ROS generation (Figure 2E). For a
positive control, mitochondrial ROS generation was detected in cells treated with hydrogen peroxide.
This result suggests that KY-20-22 may induce cell death by generating mitochondrial ROS.
Int. J. Mol. Sci. 2020, 21, 5777 4 of 17
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MB-231 (A) and MDA-MB-468 (B) cells treated with different concentrations (0–50 µM) of KY-20-22 
for different time intervals (0–72 h). Trypan blue exclusion assay of MDA-MB-231 (C) and MDA-MB-
468 (D) cells treated with different concentrations of KY-20-22 (0–50 µM) for 72 h. (E) MTT assay and 
(F) trypan blue exclusion assay of T47D cells treated with different concentrations (0–100 µM) of KY-
20-22 for 72 h. Each data point represents the mean ± SD from three independent experiments, *p < 
0.05, **p < 0.01, and ***p < 0.001 (vehicle control vs. treatment groups). 
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Figure 1. Effect of KY-20-22 on cell survival and growth of triple negative breast cancer TNBC and T47D
cell lines. MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay of MDA-MB-231
(A) and MDA-MB-468 (B) cells treated with different concentrations (0–50 µM) of KY-20-22 for different
time intervals (0–72 h). Trypan blue exclusion assay of MDA-MB-231 (C) and MDA-MB-468 (D) cells
treated with different concentrations of KY-20-22 (0–50 µM) for 72 h. (E) MTT assay and (F) trypan blue
exclusion assay of T47D cells treated with different concentrations (0–100 µM) of KY-20-22 for 72 h.
Each data point represents the mean ± SD from three independent experiments, * p < 0.05, ** p < 0.01,
and *** p < 0.001 (vehicle control vs. treatment groups).
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0.05) was observed with 100 µM of KY-20-22 (Figure 3A). Similarly, the growth of MCF-10A was not 
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Figure . Effect of KY-20 2 on colony formation nd mitochondrial ROS generation. Colony formation
f (A,B) MDA-MB-231 and (C,D) MDA-MB-468 cells treated with different concentrations of KY-20-22
(0–50 µM) for different time intervals (0–72 h). After the treatment period, cells were washed and
allowed to grow in normal growth medium for 14 days and then stained with crystal violet. Histograms
represent the number of colonies counted using an i verted microscope. (E) MDA-MB-231 cells
treated with a 25 µM concentration of KY-20-22. H2O2-treated cells were used as a positive control.
Mitochondrial ROS generation was measured as mentioned in the materials and methods. Each data
point represents the mean ± SD from three independent experiments, * p < 0.05, ** p < 0.01, and
*** p < 0.001 (vehicle control vs. treatment groups).
2.2. Effect of KY-20-22 on Normal Human Mammary Epithelial Cells
To assess the toxicity of KY-20-22 on non-cancerous cells, the cell survival of MCF10A, a normal
human mammary epithelial cell, was used for further studies. MCF10A was treated with different
concentrations of KY-20-22. The result showed that a dose of up to 50 µM of KY-20-22 did not inhibit
the survival of MCF10A cells. A significant inhibition of MCF10A cell survival (28% inhibition,
p < 0.05) was observed with 100 µM of KY-20-22 (Figure 3A). Similarly, the growth of MCF-10A was
not significantly decreased by KY-20-22 at lower concentrations (0–50 µM), however, a significant
decrease was observed at a 100 µM concentration (Figure 3B). The IC50 of KY-20-22 required for TNBC
cell inhibition was 5 µM and this concentration did not induce cytotoxicity in MCF10A cells. This result
indicates that a lower dose of KY-20-22 is relatively safe in normal breast epithelial cells.
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To further investigate the action of KY-20-22 on TNBC tumor migration, we studied epithelial–
mesenchymal transcription (EMT), which is associated with TNBC progression and migration. 
Figure 3. Effect of KY-20-22 on cell survival and growth of MCF10A cells. (A) MTT assay of MCF10A
cells treated with different concentrations (0–100 µM) of KY-20-22 for 72 h. (B) Trypan blue exclusion
assay of MCF10A cells treated with different concentrations of KY-20-22 (0–50 µM) for 72 h. Each data
point represents the mean ± SD from three independent experiments, * p < 0.05, and ** p < 0.01 (vehicle
control vs. treatment groups).
2.3. 1-Chromonyl-5-Imidazolylpentadienone KY-20-22 Regulates Genes Involved in Tumor Migration and
Inhibits the Migration of TNBC Cell Lines
Our previous studies demonstrated that the combination of curcumin and quercetin significantly
reduced the migration of TNBC cell lines compared to individual treatments of curcumin and
quercetin [8]. In the present study, a Boyden chamber assay was carried out to investigate the effect of
1-chromone-5-imidazolepentadienone KY-20-22 on the migration of TNBC cell lines. We found that
treatment with KY-20-22 dose-dependently reduced the migration of MDA-MB-231 cells. The group
treated with 10 µM of KY-20-22 exhibited an 80% reduction in the migratory cells compared to the
vehicle control (p < 0.001) (Figure 4A,B).
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Figure 4. Effect of KY-20-22 on cell migration. (A) Boyden chamber assay of MDA-MB-231 cells treated
with KY-20-22 (1 and 10 µM), f r 24 h. (B) Histogram repres ts the number of cells migrated through
he porous membrane in different treatment conditions. Each data point represents th mean ± SD
from t ree independ nt exp r ments, * p < 0.05, ** p < 0.01, and *** p < 0.001 (vehicle control vs.
treatment groups).
To further investigate the action of KY-20-22 on TNBC tumor migration, we studied
epithelial–mesenchymal transcription (EMT), which is associated with TNBC progression and migration.
Studies were carried out to analyze whether the expression levels of EMT biomarkers may be regulated
by KY-20-22 treatment. E-cadherin is one of the biomarkers for epithelial phenotype, and the expression
level of E-cadherin is low in mesenchymal cells. Treatment with KY-20-22 (10 µM) significantly
increased the E-cadherin expression level for both MDA-MB-231 and MDA-MB-468 cells (two-fold,
p < 0.05) (Figure 5A,B). A decrease in E-cadherin levels associated with an increase in N-cadherin,
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called “cadherin switching”, is a feature of EMT in cancer metastasis [32,33]. The present study
detected a dose-dependent decrease in N-cadherin expression with the treatment of KY-20-22, with
an approximately five-fold decrease (p < 0.01) with 10 µM treatment (Figure 5C,D). Another protein
that plays a significant role in cancer cell migration is matrix metalloprotease 9 (MMP-9), the higher
expression of which correlates with breast cancer metastasis. Our study determined that treatment
with KY-20-22 (10 µM) significantly reduced the expression levels of MMP-9 in both MDA-MB-231
and MDA-MB-468 cells (p < 0.001) (Figure 5E,F). All of these results demonstrate that KY-20-22
significantly reduces MDA-MB-231 migration and regulates the signaling molecules involved in EMT
and cancer metastasis.
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Specifically, survival was shorter among patients with higher IL-6 expression compared to patients 
with lower IL-6 expression. Thus, the expression levels of IL-6 were analyzed in MDA-MB-231 and 
Figure 5. Effect of KY-20-22 on epithelial-mesenchymal transition [EMT] markers. The mRNA
expression levels of E-cadherin (A,B), N-cadherin (C,D), and matrix metalloproteinase-9 [MMP-9]
(E,F) were analyzed in MDA-MB-231 cells treated with KY-20-22 for 48 h. E-cadherin and N-cadherin
expression levels were normalized to GAPDH expression. Each data point represents the mean ± SD
from three independent experiments, * p < 0.05, ** p < 0.01, and *** p < 0.001 (vehicle control vs.
treatment groups).
2.4. 1-Chromonyl-5-Imidazolylpentadienone KY-20-22 Downregulates Interleukin-6 (IL-6) Expression
The present study demonstrated that 1-chromonyl-5-imidazolylpentadienone KY-20-22 inhibits
the proliferation and migration of TNBC cell lines. Moreover, our experiments suggested that KY-20-22
increases mitochondrial ROS levels. To further understand the effect of this compound against TNBC,
we carried out studies on the action of KY-20-22 on specific cytokines that cause chemotherapy
resistance in TNBC. IL-6 is one of the signaling molecules that contributes to chemotherapy resistance
in breast cancer [34]. Hartman et al. reported that IL-6 is a key signaling molecule involved in TNBC
tumor growth and is also associated with poor overall patient survival [35]. Furthermore, our search
using The Cancer Genome Atlas (TCGA) database [36,37] confirmed that IL-6 expression influences
the survival of TNBC and ER-negative patients (Figure 6A,B). Specifically, survival was shorter among
patients with higher IL-6 expression compared to patients with lower IL-6 expression. Thus, the
expression levels of IL-6 were analyzed in MDA-MB-231 and MDA-MB-468 cells after being exposed
to KY-20-22. The results suggested that the expression of IL-6 was dose-dependently decreased with
KY-20-22 treatment (Figure 6C,D). An approximately three-fold decrease was observed with 10 µM of
KY-20-22 in MDA-MB-231 cells (p < 0.01), and a two-fold decrease in MDA-MB-468 cells (p < 0.001).
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Figure 6. Overall survival rate of TNBC and estrogen receptor nega ive (ER− ) patients with higher
expression of IL-6 and the effect of KY-20-22 on IL-6 expression. Data from the TCGA database
containing different br ast cancer subtype , such as TNBC and ER−, were extracted and used to
generate a ov r ll survival cur e using the cBio Cancer Genomics Portal [36,37]. (A) TNBC and
(B) ER− patient survival rate with a high expression of IL-6. The mRNA expression level of IL-6 in
MDA-MB-231 (C) and MDA-MB-468 (D) cells treated with KY-20-22 for 48 h. IL-6 expression was
normalized to GAPDH expression. Each data point represents the mean ± SD from three independent
experiments, * p < 0.05, ** p < 0.01, and *** p < 0.001 (vehicle control vs. treatment groups).
2.5. Synergistic Action of KY-20-22 and Paclitaxel Against TNBC
It was found that 1-chromonyl-5-imidazolylpentadienone KY-20-22 significantly decreased TNBC
growth and survival. Furthermore, to identify whether KY-20-22 increases the anti-cancer action of a
chemotherapy drug, we studied the combined action of paclitaxel and KY-20-22 in TNBC cell lines.
Initially, we studied the dose-dependent effect of paclitaxel on the survival of MDA-MB-468 and
MDA-MB-231 cells (Figure 7A). Then, cell survival analysis was carried out using a combination of
paclitaxel (5 and 10 nM for MDA-MB-231 and 1 and 5 nM for MDA-MB-468) and different concentrations
of KY-20-22 (0.5, 1, and 5 µM). CompuSyn software was used to analyze the combination index (CI)
of the combined action of KY-20-22 and paclitaxel. The CI of inhibition of cell survival was below
one (CI < 1) with a combination of KY-20-22 (1 µM and 5 µM) and paclitaxel (MDA-MB-231 5 and
10 nM, MDA-MB-468 1 and 5 nM) (Table 1). This result indicates that KY-20-22 and paclitaxel act
synergistically to inhibit the survival of TNBC cells. Figure 7B,C represent the combined action of
paclitaxel (10 nM for MDA-MB-231 and 5 nM for MDA-MB-468) and KY-20-22 (0.5, 1, 5 µM), with
results that indicate that the survival of paclitaxel- and KY-20-22-treated cells was significantly lower
compared to individual treatment with either KY-20-22 or paclitaxel.
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Table 1. Combination of KY-20-22 and paclitaxel on cell survival assay.
MDA-MB-231
KY-20-22 (µM) Paclitaxel (nM) Survival (%) Combination Index
0.5 5 70.35 2.195
0.5 10 44.50 0.879
1 5 60.48 1.85
1 10 37.63 0.678
5 5 35.48 0.569
5 10 26.8 0.365
MDA-MB-468
KY-20-22 (µM) Paclitaxel (nM) Survival (%) Combination Index
0.5 1 68.32 1.860
0.5 5 45.67 0.966
1 1 50.25 1.324
1 5 7.69 0.453
5 1 45.89 0.841
5 5 15.45 0.312
A cell survival (MTT) assay was carried out for MDA-MB-231 and MDA-MB-468 cells. Cells were
treated with different concentr tions of KY-20-22 and paclitaxel individu lly and in combination, as
indicat d in Table 1, for 72 h. CompuSyn software was used to calculate the combination index (CI) of
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the combined effect. The synergistic action of KY-20-22 and paclitaxel was determined based on the CI
theorem (additive effect (CI = 1), synergism (CI < 1), and antagonism (CI > 1) in drug combinations).
Furthermore, colony formation analysis was carried out to assess the combined action of KY-20-22
(1 µM) and paclitaxel (10 nM for MDA-MB 231 and 5 nM for MDA-MB-468) on the growth of
MDA-MB-231 and MDA-MB-468 cells, which revealed that the colonies formed with the combined
treatment were significantly reduced with the individual treatment for both cell lines (Figure 7D,E)
(p < 0.001). These results suggest that KY-20-22 significantly enhances the anti-proliferative action of
paclitaxel. Furthermore, a Boyden chamber assay, carried out to assess whether KY-20-22 enhances
the anti-migratory action of paclitaxel, revealed that the migration of MDA-MB-231 was significantly
(p < 0.01) inhibited by the combination of KY-20-22 and paclitaxel treatment compared to individual
treatment (Figure 8A).
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ROS generation. (A) Boyden chamber assay of MDA-MB-231 cells treated with paclitaxel and KY-20-22
for 24 h. Histograms represent the number of cells that migrated through the porous membrane
in different treatment conditions. (B) MDA-MB-231 cells were treated with paclitaxel (10 µM) and
KY-20-22 (25 µM) and mitochondrial ROS generation was measured for 10 min as mentioned in the
Materials and Methods (the ROS study used a much higher concentration of drugs than the other
studies because ROS generation was measured within 10 min of drug response). * p < 0.05, ** p < 0.01,
and *** p < 0.001, ## p < 0.01, (paclitaxel vs. paclitaxel + KY-20-22 or KY-20-22 vs. paclitaxel + KY-20-22).
2.6. Combined Action of KY-20-22 and Paclitaxel on Reactive Oxygen Species Generation
We found that a combination of KY-20-22 and paclitaxel synergistically inhibited the survival
and colony formation of MDA-MB-231 and MDA-MB-468 cells, but studies also suggested that
KY-20-22 alone induced ROS generation in MDA-MB-231 cells. To learn more, we carried out further
experiments to determine the effect of the combination of paclitaxel and KY-20-22 on ROS generation
in MDA-MB-231 cells. Our findings suggest that the ROS generation was significantly higher in the
paclitaxel and KY-20-22 cells compared to individual treatment with paclitaxel, however, there was no
significant change when compared to KY-20-22 alone (Figure 8B). Further in vivo studies are required
to confirm the combined action of paclitaxel and KY-20-22 against TNBC.
3. Discussi n
Most chemotherapeutics induce cell cycle arrest and cell death by generating ROS, hence ROS
exhibits tumor-suppressing action in different cancer cells [38]. In the present study, we detected that a
1-chromonyl-5-imidazolylpentadienone dose-dependently generated ROS and inhibited the growth
and survival of the TNBC cell lines MDA-MB-231 and MDA-MB-468 (Figure 1A–D and Figure 2E).
Furthermore, the 1-chromonyl-5-imidazolylpentadienone named KY-20-22 regulated “cadherin
switching”, increasing E-cadherin expression and decreasing N-cadherin expression in MDA-MB-231
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cells (Figure 5A–D). These results suggested that the 1-chromonyl-5-imidazolylpentadienone induced
anti-cancer action in TNBC cell lines. Moreover, when we combined KY-20-22 with paclitaxel,
the combination synergistically decreased the growth of MDA-MB-231 and MDA-MB-468 cells
(Figure 7B–E).
Traditionally, curcumin is used as an anti-inflammatory agent in various parts of the world, and
recently it has been identified as possessing anti-cancer activity. Combination therapy approaches,
such as the co-administration of curcumin with other dietary components, have shown further
benefit in inhibiting cancer growth and metastasis [16–18]. Combining curcumin with specific dietary
molecules not only increased anti-cancer action but also improved the absorption and bioavailability
of curcumin. For instance, the administration of curcumin with piperine, a compound in black
pepper, increases the anticancer action of curcumin against colorectal cancer [16] and reduces cancer
stem cells in breast cancer [17]. The combined anti-cancer action of curcumin and quercetin has
been reported by us and other investigators [8,24,25,29]. In the present study, we found that the
1-chromonyl-5-imidazolylpentadienone KY-20-22 inhibited the survival and proliferation of TNBC
cells dose-dependently, with an IC50 value of approximately 5 µM (Figure 1A–D). Various reports
indicated that the anti-cancer action of curcumin was mediated through increased ROS generation [5].
The findings indicate that the 1-chromonyl-5-imidazolylpentadienone KY-20-22 carries out the biological
action of both curcumin and quercetin in generating the anti-proliferative actions and ROS generation.
Alterations in the PI3K/AKT/mTOR pathway are common in TNBC [39]. Moreover, there are reports
indicating that the individual action of curcumin and quercetin could regulate the PI3K/Akt/mTOR
signaling pathways [40,41]. Hence, the anti-proliferative action of KY-20-22 may be due to the
regulation of this pathway. It has been found that mTOR signaling is not only deregulated in cancer
but also in different pathological conditions and the mTOR pathway is critical to the pathogenesis of
HIV-related malignancies [42] and different autoimmune diseases [43]. Hence, KY-20-22 might also
be effective in treating different pathological conditions which exhibit deregulated PI3K/Akt/mTOR
signaling. Furthermore, 1-chromonyl-5-imidazolylpentadienone KY-20-22 (10 µM) significantly
(p < 0.01) increased E-cadherin expression and decreased N-cadherin levels in both MDA-MB-231 and
MDA-MB-468 cells (Figure 5A–D). These results indicated that KY-20-22 is able to induce “cadherin
switching” in TNBC cells. TNBC, a very aggressive breast cancer compared to other subtypes, is a
heterogeneous cancer with basal-like and claudin-low TNBC being the major subtypes. Notably, only a
portion of basal-like breast cancers are TNBC (77%) [44]. Studies have suggested that basal-like TNBC
is associated with mesenchymal features and with a higher expression of EMT genes and a lower
expression of E-cadherin or E-cadherin loss [32,44,45]. While our study revealed that the KY-20-22
molecule could modulate the EMT process and alter the mesenchymal features of TNBC, further
in vivo studies are required to confirm this.
We found that KY-20-22 significantly reduced MMP-9 expression in MDA-MB-231 cells
(Figure 5E,F). MMP-9 expression is regulated by various cytokines and growth factors, with the
cytokine IL-6 regulating MMP-9 in macrophage cells [46]. Higher expression levels of IL-6 and IL-8
contribute to TNBC proliferation and metastasis [47] and, moreover, a higher expression of IL-6 is
associated with chemotherapy resistance in breast cancer [47,48]. Rincon et al. reported that the
response to paclitaxel is lower in breast cancer patients with a higher expression level of IL-6 [48].
In the present study, we used TCGA analysis, which is routinely used to identify novel therapeutic
targets in different types of cancers [36,37]. We detected that higher IL-6 expression reduces the
survival rate of TNBC and ER-negative patients (Figure 6A,B). All of this information indicates that
IL-6 plays a significant role in the pathology of TNBC. We observed significantly lower levels of IL-6
expression in KY-20-22-treated TNBC cells (Figure 6C,D). One of the major events associated with IL-6
binding to its receptor is the activation of signal transducers and activators of transcription-3 (STAT-3).
Various studies have indicated that STAT-3 is a molecular target for curcumin via IL-6 modulation
for various cancer types [3]. Hence, further studies are required to confirm the action of KY-20-22
in inhibiting the signaling of STAT-3 in TNBC cells. Moreover, IL-6 is a major cytokine involved in
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different autoimmune diseases. Hence, KY-20-22 might have therapeutic action towards autoimmune
diseases such as rheumatoid arthritis, which is treated with the anti-IL-6 receptor tocilizumab [49].
Additionally, we detected that the combination of paclitaxel and KY-20-22 induced a synergistic
anti-cancer action against TNBC. Our studies suggested that low concentrations of paclitaxel (5–10 nM)
and 1 µM of KY-20-22 inhibited 60–70% of MDA-MB-231 and MDA-MB-468 cell survival (Figure 7B,C).
Moreover, the migration of MDA-MB-231 cells was significantly reduced by the combination of
KY-20-22 and paclitaxel compared to individual treatment (Figure 8A). Furthermore, various studies
reported that curcumin and its analogs increase sensitivity to chemotherapeutic drugs by reversing the
multidrug resistance of cancer cells [50,51]. The combined action of paclitaxel and KY-20-22 on TNBC
cells may be due to the action of KY-20-22 on multidrug resistance proteins. The induction of cancer
cell apoptosis by various chemotherapeutic drugs is associated with cellular ROS generation [38].
The level of ROS generation varies for different drugs, and cellular ROS production is higher for
doxorubicin, epirubicin, and daunorubicin and lower for taxanes, vinca alkaloids, and nucleotide
analogs [52]. A decrease in cellular anti-oxidant levels and mitochondrial ROS generation are the
reasons behind chemotherapy-induced cellular levels in ROS. Hence, it is worthwhile to identify
compounds that target ROS levels to treat solid tumors [53]. In this study, we found that the combination
of paclitaxel and KY-20-22 significantly increased ROS generation compared to paclitaxel treatment
alone in MDA-MB-231 cells (Figure 8B). Therefore, it is possible that the combination of KY-20-22
with paclitaxel increases the anti-cancer activity of paclitaxel or reduces paclitaxel resistance in TNBC.
However, further in vivo studies are required to confirm the combined action of paclitaxel and KY-20-22
in the TNBC animal model. Moreover, our study found that KY-20-22 is not toxic to normal mammary
cells at the dose required for TNBC cell inhibition. Future animal studies are essential for the detection
of the therapeutic index of KY-20-22.
Studies on the pharmacokinetics of KY-20-22, including its absorption, bioavailability, and
metabolism, are also needed to confirm the novelty of this compound. In particular, the
bioavailability of curcumin/quercetin has been considered a major limitation to achieving their
biological activity in the in vivo system [13]. The preparation of various curcumin/quercetin analogs
and different formulations have been explored to increase the bioavailability of these compounds [14].
The 1-chromonyl-5-imidazolylpentadienone KY-20-22 is prepared by inserting specific moieties to
overcome this limitation. However, our present study did not evaluate the bioavailability of KY-20-22
in any system.
In conclusion, the findings of our present study suggest that the 1-chromonyl-5-
imidazolylpentadienone KY-20-22 induced an anti-proliferative effect and enhanced ROS generation in
TNBC cells. Furthermore, KY-20-22 regulated different EMT markers and decreased the expression of
signaling molecules such as MMP-9 and IL-6. A combination of KY-20-22 and paclitaxel demonstrated
a synergistic effect on TNBC growth reduction. These results indicate that KY-20-22 is a novel molecule
that encompasses the biological action of both curcumin and quercetin in inducing anti-cancer action
in TNBC. Further in vivo studies are required to evaluate the TNBC tumor-reducing efficacy and
bioavailability of KY-20-22.
4. Materials and Methods
4.1. Materials
First, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from
Sigma-Aldrich (St. Louis, MO, USA). MDA-MB-231, MDA-MB-468, and T47D breast cancer cell lines
were purchased from ATCC (Manassas, VA, USA). An RNA isolation kit was purchased from Qiagen
(Germantown, MD, USA). Taqman gene expression assays and master mix for quantitative polymerase
chain reaction (PCR) were purchased from Life Technologies (Waltham, MA, USA).
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4.2. 1-Chromonyl-5-Imidazolylpentadienone Synthesis
The original design of 3-((1E,4E-5-(1-ethyl-1H-imidazol-2-yl)-3-oxopenta-1,4-dien-1-yl)-4H-
chromen-4-one was driven by the notion that appreciable synergistic effects can be achieved
by integrating two or more privileged pharmacophores into one single hybrid compound [54].
The pharmacophores used were (1E,4E)-1,5-diaryl-1,4-penta-dien-3-one and chromone from curcumin
and quercetin, respectively (Figure 9). The hybrid compound KY-20-22 was prepared via an aldol
condensation of 3-formylchromone with (E)-4-(1-ethyl-1H-imidazol-2-yl) but-3-en-2-one according to
the procedure reported earlier [30]. Its 1H NMR and 13C NMR data are consistent with those reported
in the literature [54].
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Figure 9. Structure of (A) quercetin (B) curcumin and (C) KY-20-22 (chemical name:
3-((1E,4E-5-(1-ethyl-1H-imidazol-2-yl)-3-oxopenta-1,4-dien-1-yl)-4H-chromen-4-one, chemical formula:
C19H16N2O3, exact mass: 320.1161).
4.3. Cell Culture
TNBC cell lines (MDA-MB-231 and MDA-MB-468), and ER-positive (T47D) cells were grown in
RPMI medium containing 1% penicillin–streptomycin and 10% fetal bovine serum (FBS) at 37 ◦C in
5% CO2. MCF10A (normal human mammary epithelial) cells were grown in DMEM/F12 medium
containing horse serum (5%), EGF (20 ng/mL), hydrocortisone (0.5 mg/mL), cholera toxin (100 ng/mL),
insulin (10 µg/mL), and 1% penicillin–streptomycin.
4.4. Cell Growth and Survival Assays
The cell survival of KY-20-22 was determined in MDA-MB-231, MDA-MB-468, T47D, and MCF10A
cells. Initially, the cells (5 × 103 cells/well) were plate in 96-well plates for 24 h. The ttached cells
were treated with different concentrations of KY-20-22 (0–50 µM) for 72 h. Control cells were treated
with vehicle (low concentration of DMSO that is present in KY-20-22). Cells were treated with 10 µL
MTT (5 mg/mL) for 4 h after the treatment period. The plat was incubate for ov rnight after adding
a solubilization reagent to dissolve the purple precipitate obtained from MTT. The absorbance at
570 nm and 650 nm was measured using a microplate reader. The cell growth of KY-20-22-treated
MDA-MB-231, MDA-MB-468, T47D, and MCF10A cells was analyzed using trypan blue staining.
The different concentrations of KY-20-22 used in these experiments are mentioned in respective
figure legends.
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4.5. Colony Formation Assay
MDA-MB-231 and MDA-MB-468 cells were plated at a density of 0.2 × 106 cells in 24-well plates
and treated with KY-20-22 as indicated in the figure legends. The cells treated with vehicle and KY-20-22
were allowed to grow for 2 weeks to form colonies. The growth medium was replenished in a 72 h
time interval in all the samples. After 2 weeks, the cells were washed with PBS, fixed with methanol,
and stained with crystal violet (0.5% w/v). The images of the stained cells were taken using an inverted
microscope and the colonies were counted.
4.6. Boyden Chamber Assay
MDA-MB-231 and MDA-MB-468 cells (2.5 × 103) were exposed to KY-20-22 (1 µM and 10 µM).
After 24 h, cells were seeded in Boyden chambers containing matrigel (BioCoat, Franklin Lakes,
NJ, USA) and chambers were placed in a 24-well culture dish containing complete growth medium
supplemented with chemo-attractant. After 24 h, the migrated/invaded cells on the lower surface of
the membrane were stained with crystal violet and counted.
4.7. Quantitative RT-PCR Analysis
Isolated total RNA from KY-20-22-treated MDA-MB-231 and MDA-MB-468 cells were reverse
transcribed using a Verzo cDNA kit (ThermoFisher Scientific, Waltham, MA). Quantitative RT-PCR
of E-cadherin (assay ID: Hs 01023895_m1), N-cadherin (assay ID: Hs 00983056_m1), MMP-9 (assay
ID: Hs 00234579_m1), and IL-6 (assay ID: Hs 00985641_m1) were carried out using TaqMan gene
expression assay method (Life Technologies, Waltham, MA, USA). GAPDH (assay ID: HS02758991_g1)
expression was used to normalize mRNA expression levels.
4.8. Detection of Mitochondrial ROS Accumulation
The measurement of mitochondrial ROS levels was carried out using the MitoSOX Red superoxide
indicator (Molecular Probes, Fisher Scientific), a highly selective fluorogenic dye, as previously
reported [55]. MitoSOX Red reagent permeates live cells, and rapidly and selectively targets
mitochondria. At the mitochondrial level, it is rapidly oxidized by superoxide; the oxidation of
MitoSOX reagent leads to red fluorescence. Cells were incubated with 3 µM MitoSOX Red in Hanks’s
balanced salt solution (HBSS) at room temperature for 25 min in the dark, and washed with dye-free
HBSS. The intensity of red fluorescence after excitation at 510 nm was acquired at a frequency of
0.25 Hz and evaluated as a measure of mitochondrial superoxide accumulation.
4.9. Statistical Analyses
Statistical analyses were performed using GraphPad Prism (version 8.0) software (GraphPadPrism
Software, Inc. San Diego, California). Multiple analyses comparing to the vehicle control were carried
out using one-way ANOVA followed by Dunnett’s test. A Student’s t-test was used to compare two
groups (paclitaxel or KY-20-22 vs. paclitaxel + KY-20-22). For all experiments, p < 0.05 was considered
significant. CompuSyn software was used to analyze the combination index of the combined action of
KY-20-22 and paclitaxel. A synergistic action of KY-20-22 and paclitaxel was determined based on
the Combination Index CI theorem of Chou–Talalay (additive effect CI = 1, synergism CI < 1, and
antagonism CI > 1) [56].
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